Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9917605rdf:typepubmed:Citationlld:pubmed
pubmed-article:9917605lifeskim:mentionsumls-concept:C0115137lld:lifeskim
pubmed-article:9917605lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:9917605lifeskim:mentionsumls-concept:C0033213lld:lifeskim
pubmed-article:9917605lifeskim:mentionsumls-concept:C0040508lld:lifeskim
pubmed-article:9917605lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:9917605lifeskim:mentionsumls-concept:C1511545lld:lifeskim
pubmed-article:9917605lifeskim:mentionsumls-concept:C1706387lld:lifeskim
pubmed-article:9917605pubmed:issue355lld:pubmed
pubmed-article:9917605pubmed:dateCreated1999-2-10lld:pubmed
pubmed-article:9917605pubmed:abstractTextSurgeons who perform arthroplasties have posed some critical questions about hydroxyapatite. Does hydroxyapatite coating enhance bone ingrowth or ongrowth? Will hydroxyapatite lead to increased polyethylene wear or an increased incidence of osteolysis? Will the hydroxyapatite coating disappear, and if so, what will be left to maintain implant fixation? A multicenter study of 316 hips (282 patients) with a proximally hydroxyapatite coated stem and either a hydroxyapatite or porous coated cup were followed up 8.1 years (range, 5.6-9.9 years). The average patient age was 50 years (range, 16-81 years), and 61% of the patients were male. One (0.3%) stem, three (2.7%) porous coated cups, and 25 (11.9%) hydroxyapatite coated cups were revised for aseptic loosening. Disappointing results on the acetabular side indicate that substrate design is critical. There were no cases of intramedullary femoral osteolysis, and the incidence of acetabular and proximal femoral osteolysis- and polyethylene wear was no greater than that seen with other cementless or cemented components. Based on these clinical results and a critical review of the literature, it is concluded that hydroxyapatite coated hip components do enhance ingrowth or ongrowth with no increased incidence of osteolysis for as many as 10 years. Concern about the disappearance of the hydroxyapatite coating with time seems moot in light of the above clinical findings.lld:pubmed
pubmed-article:9917605pubmed:languageenglld:pubmed
pubmed-article:9917605pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9917605pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9917605pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9917605pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9917605pubmed:statusMEDLINElld:pubmed
pubmed-article:9917605pubmed:monthOctlld:pubmed
pubmed-article:9917605pubmed:issn0009-921Xlld:pubmed
pubmed-article:9917605pubmed:authorpubmed-author:CapelloW NWNlld:pubmed
pubmed-article:9917605pubmed:authorpubmed-author:ManleyM TMTlld:pubmed
pubmed-article:9917605pubmed:authorpubmed-author:D'AntonioJ...lld:pubmed
pubmed-article:9917605pubmed:authorpubmed-author:FeinbergJ RJRlld:pubmed
pubmed-article:9917605pubmed:issnTypePrintlld:pubmed
pubmed-article:9917605pubmed:ownerNLMlld:pubmed
pubmed-article:9917605pubmed:authorsCompleteYlld:pubmed
pubmed-article:9917605pubmed:pagination200-11lld:pubmed
pubmed-article:9917605pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:meshHeadingpubmed-meshheading:9917605-...lld:pubmed
pubmed-article:9917605pubmed:year1998lld:pubmed
pubmed-article:9917605pubmed:articleTitleHydroxyapatite in total hip arthroplasty. Clinical results and critical issues.lld:pubmed
pubmed-article:9917605pubmed:affiliationDepartment of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis 46202-5111, USA.lld:pubmed
pubmed-article:9917605pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9917605pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9917605pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:9917605pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9917605lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9917605lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9917605lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9917605lld:pubmed